Stock Forecast Based On a Predictive Algorithm | I Know First |GILD Archives - Page 14 of 16 - Stock Forecast Based On a Predictive Algorithm

Quantitative Finance Utilizing Algorithmic Predictions: Up To 31.53% Return in 3 Months

January 4, 2016

Package Name: Top 10 Stocks
Forecast Length: 3 month (9/30/15 - 12/30/15)
I Know First Average: 14.55%

Best Blue Chip Stocks: 3.21% Average Return in 7 Days

August 5, 2015

Package Name: Best Mega Cap Stocks
Forecast Length: 7 Days (7/28/15 - 8/04/15)
I Know First Average: 3.21%

Gilead Sciences Stock Outlook: An Algorithmic Analysis (GILD)

August 3, 2015

I Know First published a bullish article on Gilead Sciences, a biotech firm that specializes in the Hepatitis C and HIV markets. Having explained how I Know First’s algorithm works, it is worthwhile to see if the algorithm agrees with the bullish fundamental analysis of the company. The three-month and one-year forecasts for Gilead Sciences are included.

Algorithmic Articles

Best Short Term Stocks based on Algorithms: An Average Return of 8.55% In 1 Week

July 22, 2015

Package Name: Industry Package - Biotech Stocks
Forecast Length: 1 Week (07/14/15 – 7/21/15)
I Know First Average: 8.55%

Read The Full Forecast

Biotech Stocks Forecast

Algorithmic Analysis Based On Machine Learning: Up To 111.51% Return in 3 Months

July 14, 2015

Package Name: Industry Package - Biotech Stocks
Forecast Length: 3 Months (4/5/15 – 7/5/15)
I Know First Average: 14.63%

Read The Full Forecast

Biotech Stocks Forecast

Gilead Stock Analysis: Buy Ahead Of The Upcoming Earnings (GILD)

July 14, 2015

Summary

Gilead Sciences has fallen over 6% since reaching an all time high on June 23rd.
The recent pullback is a great investing opportunity for long-term investors as concerns over HCV competition are overblown.
The valuation is very cheap, and the company is reducing its reliance on the HCV market.
I Know First Algorithm is bullish on Gilead Sciences in the long-term and believe it will reach new record highs.

Long-term investors should continue adding this stock at current prices. The recent pullback is a prime investing opportunity, as this stock is the most attractive option in not only the biotech sector, but quite possible of any stock on the market. The recent news that Harvoni was approved in Japan offers plenty of extra room for revenue growth, and the market in the US is far from drying out. Along with the new TFA drug trials for HIV patients and the potential for an acquisition to bolster its oncology offerings, there is plenty to be excited about moving forward.

Read The Full Article Here

Algorithmic Performance

Gilead Sciences Stock Forecast: Buy GILD Ahead Of The Upcoming Earnings

July 12, 2015

I Know First published a bullish article on Gilead Sciences, a technology company offering search and content on mobile and desktop devices, on Seeking Alpha. Having explained how I Know First’s algorithm works, it is worthwhile to see if the algorithm agrees with the bullish fundamental analysis of the company. The three-month and one-year forecasts for Gilead Sciences are included.